Announcements Trials
Browse Landscape

Phase

Phase NA 44Phase 2 3Phase 4 2Phase 3 2Phase EARLY_PHASE1 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 5Gastrointestinal 5CNS 5Lymphoid 4Sarcoma 3Other solid neoplasm 2Gynecologic 2Dermatologic 2Breast 2Tumor-Agnostic 1Thoracic 1Plasma cell 1Other hematologic neoplasm 1Myeloid 1Head & Neck 1Endocrine 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 156Carboplatin 146Cisplatin 129Pemetrexed 103Paclitaxel 89Nivolumab 71Radiotherapy 68Docetaxel 61Erlotinib Hydrochloride 58Gemcitabine 57Etoposide 44osimertinib 43Bevacizumab 43Cyclophosphamide 42durvalumab 41atezolizumab 35Cetuximab 33130-nm albumin-bound paclitaxel 26Radiosurgery 25fludarabine 23Ipilimumab 23Irinotecan 21Taxes 20Radiation 20Oxaliplatin 20Magnetic Resonance Spectroscopy 20Fluorouracil 20Gefitinib 19Everolimus 19Topotecan 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Blood Specimen Collection × Thoracic × Clear all
NCT07436858 2026-02-27

Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer

The Netherlands Cancer Institute

Phase 1 Not yet recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡